Graft Versus Leukemia: Current Status and Future Perspectives
Ce dossier présente un ensemble d'articles concernant la biologie et le traitement par immunothérapie de cancers hématologiques
Relapse of hematologic malignancy is the major reason for treatment failure after allogeneic stem cell transplantation. Graft-versus-leukemia (GVL) responses are critical to prevent relapse but may fail as a result of tumor immune evasion, for example through antigen loss or T cell dysfunction. In silico pipelines for the discovery of tumor-expressed antigens and novel therapies that target immune evasion mechanisms (small molecule, biological, immune cell transfer) are potential strategies to sustain or reimpose GVL. A key challenge will be how experimental therapies to enhance GVL can progress from first-in-human trials to prospective, controlled trials that evaluate efficacy and lead to regulatory approval.